Payment overview · 2025
General Payments
$188.66
11 reported records · 7 companies
Healthcare provider profile · identity verified
Andrew A Coppola, MD
Allopathic & Osteopathic Physicians|Family Medicine · FAYETTEVILLE, AR · NPI 1831548270
Verified facts
What the public records show
CMS Open Payments records show Andrew A Coppola, MD received $188.66 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.18 | 27.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.76 | 22.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.38 | 16.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.65 | 9.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.51 | 9.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.79 | 7.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.39 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $188.66 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.38 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.38 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 70 |
| Metformin Hcl | Metformin Hcl | 284 | 79 |
| Losartan Potassium | Losartan Potassium | 267 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 57 |
| Omeprazole | Omeprazole | 216 | 54 |
| Lisinopril | Lisinopril | 206 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 48 |
| Ozempic | Semaglutide | 143 | 22 |
| Simvastatin | Simvastatin | 131 | 36 |
| Meloxicam | Meloxicam | 128 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 28 |
| Gabapentin | Gabapentin | 112 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 28 |
| Jardiance | Empagliflozin | 103 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 23 |
| Clonazepam | Clonazepam | 99 | 16 |
| Tramadol Hcl | Tramadol Hcl | 92 | 23 |
| Glimepiride | Glimepiride | 87 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 21 |
| Potassium Chloride | Potassium Chloride | 76 | 14 |
| Furosemide | Furosemide | 70 | 15 |
| Trazodone Hcl | Trazodone Hcl | 66 | 19 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 17 |
| Sertraline Hcl | Sertraline Hcl | 56 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Carvedilol | Carvedilol | 49 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 12 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Atenolol | Atenolol | 44 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 11 |
| Allopurinol | Allopurinol | 41 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Alprazolam | Alprazolam | 38 | 11 |
| Glipizide | Glipizide | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 21 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Prednisone | Prednisone | 22 | 14 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 15 |
| Temazepam | Temazepam | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 12 |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Mupirocin | Mupirocin | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Diazepam | Diazepam | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $188.66 · 11 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, ELIQUIS, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, SHINGRIX, TZIELD, UBRELVY, XIFAXAN, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error